8-K: Viking's Oral VK2735 Shows Strong Weight Loss in Phase 2

Viking Therapeutics announced positive top-line Phase 2 results for its oral VK2735 tablet, demonstrating statistically significant weight reductions in obesity patients.

Summary

• Positive top-line results from the Phase 2 VENTURE-Oral Dosing trial of VK2735 oral tablet formulation were announced.
• VK2735, a dual agonist of GLP-1 and GIP receptors, is being developed for metabolic disorders such as obesity.
• The study successfully achieved its primary and secondary endpoints, showing statistically significant reductions in body weight compared with placebo.
• Participants receiving VK2735 demonstrated up to 12.2% mean weight loss (approximately 26.6 lbs) after 13 weeks of treatment, compared with 1.3% (approximately 2.9 lbs) for placebo.
• Statistically significant reductions in mean body weight relative to placebo ranged up to 10.9%.
• Weight loss was progressive at all doses through the 13-week study period, with no plateau observed.
• Up to 97% of subjects in VK2735 treatment groups achieved at least 5% weight loss, compared with 10% for placebo.
• Up to 80% of subjects in VK2735 treatment groups achieved at least 10% weight loss, compared with 5% for placebo.
• An exploratory assessment of low-dose maintenance treatment demonstrated positive proof of concept, suggesting effective weight maintenance at doses less than 30 mg.
• VK2735 was shown to be safe and well-tolerated over the 13-week study, with 99% of GI-specific treatment emergent adverse events (TEAEs) considered mild or moderate.

Sentiment

Score: 9

Explanation: The filing reports highly positive top-line Phase 2 clinical trial results for VK2735 oral tablet, meeting primary and secondary endpoints with significant weight loss and a favorable safety profile. This represents a major de-risking event and a strong step forward for the company's obesity program.

Positives

• Statistically significant reductions in mean body weight were observed, ranging up to 12.2% from baseline and up to 10.9% relative to placebo after 13 weeks.
• Weight loss was progressive across all doses through the study, with no plateau observed, suggesting potential for further improvement with longer dosing periods.
• High rates of clinically meaningful weight loss were achieved, with up to 97% of subjects achieving 5% weight loss and up to 80% achieving 10% weight loss.
• The oral tablet formulation of VK2735 demonstrated encouraging safety and tolerability, with 98% of drug-related TEAEs and 99% of GI-related TEAEs categorized as mild or moderate.
• Discontinuation rates due to adverse events were low and well-balanced among subjects treated with VK2735 (20%) compared with placebo (13%).
• The exploratory maintenance arm provided an encouraging signal for effective weight maintenance at lower oral doses (e.g., 30 mg daily).

Negatives

• Overall treatment discontinuation rates were higher among VK2735 subjects (28%) compared to placebo subjects (18%).
• The most common reasons for treatment discontinuation were gastrointestinal (GI)-related adverse events.
• Nausea was reported among 58% of participants receiving VK2735 compared with 48% for placebo.
• Vomiting was reported in 26% of VK2735-treated subjects compared with 10% among subjects receiving placebo.

Risks

• Risks are associated with the success, cost, and timing of product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and other incretin receptor agonists.
• There is a risk that prior clinical and preclinical results may not be replicated in future studies.
• Risks exist regarding regulatory requirements and the ability to obtain necessary approvals.
• Other risks are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The progressive nature of the weight loss curves suggests the potential for further improvement with longer dosing periods. The experimental maintenance arm of this study provides an encouraging signal that supports the belief that transitioning patients from higher doses (injectable or oral) to low oral doses represents a promising approach to weight maintenance therapy. The company looks forward to exploring this further in an upcoming maintenance dosing study.

Management Comments

• "We are excited to report the top-line Phase 2 study results for the once-daily oral tablet of VK2735."
• "As in prior studies we observed a clear dose response and impressive weight loss across the 13-week treatment period."
• "The progressive nature of the weight loss curves suggests the potential for further improvement with longer dosing periods."
• "The experimental maintenance arm of this study provides an encouraging signal that supports our belief that transitioning patients from higher doses, injectable or oral, to low oral doses represents a promising approach to weight maintenance therapy."
• "We look forward to exploring this further in an upcoming maintenance dosing study."

Industry Context

The results for VK2735, a dual GLP-1/GIP receptor agonist, position it within a highly competitive and rapidly growing market for metabolic disorders, particularly obesity. Existing approved therapies like Semaglutide (Ozempic, Rybelsus, Wegovy) and Tirzepatide (Mounjaro, Zepbound) are also GLP-1 or dual GLP-1/GIP agonists. VK2735's oral formulation offers a potential advantage in patient convenience compared to injectable forms, a key differentiator in market adoption. The strong weight loss efficacy observed in this Phase 2 trial suggests VK2735 could be a significant contender, potentially offering a best-in-class oral option.

Comparison to Industry Standards

• VK2735's observed mean weight loss of up to 12.2% (10.9% placebo-adjusted) after 13 weeks compares favorably to early-stage data or shorter-duration studies of some existing GLP-1/GIP agonists. For instance, early trials of oral Semaglutide (Rybelsus) showed more modest weight loss in non-diabetic obese patients over similar durations, though direct head-to-head comparisons are complex due to trial design differences.
• The high proportion of responders (up to 97% achieving 5% weight loss, 80% achieving 10% weight loss) is competitive with leading injectable GLP-1/GIP agonists like Wegovy (semaglutide) and Zepbound (tirzepatide) over longer treatment periods, suggesting strong early efficacy for VK2735's oral form.
• The safety and tolerability profile, with 99% of GI-related adverse events being mild or moderate, appears consistent with the class effect of GLP-1/GIP agonists, which commonly report GI side effects like nausea and vomiting. Discontinuation rates due to adverse events (20% for VK2735) are within the range observed for other oral and injectable GLP-1/GIP agonists in their respective clinical trials.

Stakeholder Impact

• Shareholders: Positive results are highly likely to increase investor confidence and potentially lead to an increase in share price due to de-risking and enhanced commercial prospects for VK2735.
• Patients: The oral tablet formulation offers a convenient, non-injectable option for obesity treatment, potentially improving adherence and accessibility for patients.
• Healthcare Providers: Provides a new, effective oral treatment option for managing obesity, expanding the therapeutic arsenal.
• Competitors: Intensifies competition in the GLP-1/GIP agonist market, particularly for oral formulations.

Next Steps

• Further exploration of low-dose maintenance therapy in an upcoming maintenance dosing study.
• Ongoing evaluation of subcutaneous VK2735 in a Phase 3 obesity program, including the VANQUISH-1 and VANQUISH-2 clinical trials.

Key Dates

Recommendation

The top-line Phase 2 results for oral VK2735 are exceptionally strong, demonstrating significant weight loss efficacy comparable to or exceeding some existing therapies, coupled with a favorable safety and tolerability profile for an oral formulation. This data substantially de-risks the program and positions Viking Therapeutics as a strong contender in the lucrative obesity market. The positive proof-of-concept for maintenance dosing further enhances the long-term commercial potential. Given these highly positive clinical outcomes, the stock is likely to see significant upside, making it a strong buy for investors looking for exposure to the obesity drug market.

Keywords

Viking Therapeutics, VK2735, obesity, weight loss, GLP-1, GIP, dual agonist, Phase 2, clinical trial, metabolic disorders, biopharmaceutical, VENTURE-Oral Dosing, oral tablet